
Immunovant, Inc.: shareholders and insiders
Price
$31.77
November 20, 2026Market cap $6.5B
What Ploutos Investor adds for Immunovant
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from FY2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Nov 12, 2026, from their own Form 4 filings.
Bought on the market
$350M
1 person
Sold on the market
$16M
9 people
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan9%
- The rest91%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $15M by 8 people
- 2025: bought $350M by 1 person, sold $1.2M by 3 people
- 2026: no buys, sold $15M by 8 people
- Nov 11, 2026Atul PandeDirectorKind10b5-1
- Nov 11, 2026Atul PandeDirectorKind10b5-1
- Oct 28, 2026Tiago GiraoChief Financial OfficerKind
- Oct 21, 2026Jay S StoutChief Technology OfficerKind
- Oct 7, 2026Jay S StoutChief Technology OfficerKind
- Oct 7, 2026Jay S StoutChief Technology OfficerKind
- Oct 7, 2026Tuyl Christopher VanChief Legal OfficerKind
- Oct 7, 2026Melanie GloriaChief Operating OfficerKind
- Oct 2, 2026Eric VenkerChief Executive OfficerKind
- Oct 1, 2026Eric VenkerChief Executive OfficerKind
- Oct 1, 2026Eric VenkerChief Executive OfficerKind
- Sep 23, 2026Tuyl Christopher VanChief Legal OfficerKind
- Aug 28, 2026Atul PandeDirectorKind10b5-1
- Aug 28, 2026Atul PandeDirectorKind10b5-1
- Aug 20, 2026Melanie GloriaChief Operating OfficerKind
- Jul 24, 2026Atul PandeDirectorKind10b5-1
- Jul 24, 2026Atul PandeDirectorKind10b5-1
- Jul 23, 2026Tiago GiraoChief Financial OfficerKind
- Jul 23, 2026Jay S StoutChief Technology OfficerKind
- Jul 8, 2026Melanie GloriaChief Operating OfficerKind
- Jul 8, 2026Melanie GloriaChief Operating OfficerKind
- Jul 8, 2026Tuyl Christopher VanChief Legal OfficerKind
- Jul 8, 2026Tuyl Christopher VanChief Legal OfficerKind
- Jul 8, 2026Jay S StoutChief Technology OfficerKind
- Jul 8, 2026Jay S StoutChief Technology OfficerKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | Atul PandeDirector | 10b5-1 | 3,000 | $8.43 | $25.3K | Form 4 |
| Nov 11, 2026 | Atul PandeDirector | 10b5-1 | 3,000 | $36.00 | $108.0K | Form 4 |
| Oct 28, 2026 | Tiago GiraoChief Financial Officer | 6,606 | $28.50 | $188.3K | Form 4 | |
| Oct 21, 2026 | Jay S StoutChief Technology Officer | 2,595 | $28.94 | $75.1K | Form 4 | |
| Oct 7, 2026 | Jay S StoutChief Technology Officer | 2,213 | $32.06 | $70.9K | Form 4 | |
| Oct 7, 2026 | Jay S StoutChief Technology Officer | 1,596 | $32.06 | $51.2K | Form 4 | |
| Oct 7, 2026 | Tuyl Christopher VanChief Legal Officer | 1,327 | $32.06 | $42.5K | Form 4 | |
| Oct 7, 2026 | Melanie GloriaChief Operating Officer | 2,241 | $32.06 | $71.8K | Form 4 | |
| Oct 2, 2026 | Eric VenkerChief Executive Officer | 3,506 | $34.11 | $119.6K | Form 4 | |
| Oct 1, 2026 | Eric VenkerChief Executive Officer | 92.2K | $14.46 | $1.3M | Form 4 | |
| Oct 1, 2026 | Eric VenkerChief Executive Officer | 85.9K | $33.65 | $2.9M | Form 4 | |
| Sep 23, 2026 | Tuyl Christopher VanChief Legal Officer | 2,846 | $36.36 | $103.5K | Form 4 | |
| Aug 28, 2026 | Atul PandeDirector | 10b5-1 | 1,500 | $8.43 | $12.6K | Form 4 |
| Aug 28, 2026 | Atul PandeDirector | 10b5-1 | 1,500 | $43.27 | $64.9K | Form 4 |
| Aug 20, 2026 | Melanie GloriaChief Operating Officer | 3,056 | $44.16 | $135.0K | Form 4 | |
| Jul 24, 2026 | Atul PandeDirector | 10b5-1 | 1,500 | $8.43 | $12.6K | Form 4 |
| Jul 24, 2026 | Atul PandeDirector | 10b5-1 | 1,500 | $39.80 | $59.7K | Form 4 |
| Jul 23, 2026 | Tiago GiraoChief Financial Officer | 6,798 | $38.69 | $263.0K | Form 4 | |
| Jul 23, 2026 | Jay S StoutChief Technology Officer | 2,857 | $38.69 | $110.5K | Form 4 | |
| Jul 8, 2026 | Melanie GloriaChief Operating Officer | 1,930 | $39.53 | $76.3K | Form 4 | |
| Jul 8, 2026 | Melanie GloriaChief Operating Officer | 106 | $39.99 | $4.2K | Form 4 | |
| Jul 8, 2026 | Tuyl Christopher VanChief Legal Officer | 1,143 | $39.53 | $45.2K | Form 4 | |
| Jul 8, 2026 | Tuyl Christopher VanChief Legal Officer | 63 | $39.99 | $2.5K | Form 4 | |
| Jul 8, 2026 | Jay S StoutChief Technology Officer | 1,906 | $39.53 | $75.3K | Form 4 | |
| Jul 8, 2026 | Jay S StoutChief Technology Officer | 105 | $39.99 | $4.2K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 29, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by IMVT's officers and directors from 2019 up to November 21, 2025, 7 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 2 more, back to 2019
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
Roivant Sciences Ltd.55.9%From the filing of Dec 12, 2025
Item 4 is hereby amended by adding the following to the end thereof: Roivant purchased an aggregate of 16,666,666 shares of Common Stock in the Offering to provide further capital to the Issuer for the advancement of the Issuer's development pipeline, working capital and other general corporate purposes, as well as to increase its ownership interest in the Issuer following the Offering. As the Issuer's largest shareholder, Roivant may provide additional financing to the Issuer from time to time in the form of an investment in equity or debt securities of the Issuer or loans, including in connection with business development transactions or financing commitments in relation thereto.
From the filing of Dec 12, 2025
Fell to 5% or less (1)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- Deep Track Capital, LP4.55%Aug 14, 202613G/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Greenlight / DME (Einhorn)In the quarter-25%
- Renaissance TechnologiesIn the quarter+7.3%
- D.E. ShawIn the quarter-11%
- Millennium Mgmt (Englander)In the quarter-22%
- Citadel Advisors (Griffin)In the quarter
- AQR CapitalIn the quarter+136%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Greenlight / DME (Einhorn) | 70.1K | -25% | $2.4M | 0.07% |
| Renaissance Technologies | 779.5K | +7.3% | $26M | 0.04% |
| D.E. Shaw | 1.11M | -11% | $37M | 0.02% |
| Millennium Mgmt (Englander) | 256.8K | -22% | $8.7M | 0.01% |
| Citadel Advisors (Griffin) | – | – | 0.00% | |
| AQR Capital | 26.2K | +136% | $900.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 8.90% of its shares outstanding were held short, +4.9% since the report before.
- Shares held short
- 18.27M
- 8.90%
- Since the report before17.42M on Sep 30, 2026
- +4.9%
- 12.4
- 1.48M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 96%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 6.69M
- Nov 15, 2023: Shares held short 7.06M
- Nov 30, 2023: Shares held short 6.89M
- Dec 15, 2023: Shares held short 7.62M
- Dec 29, 2023: Shares held short 7.46M
- Jan 12, 2024: Shares held short 8.04M
- Jan 31, 2024: Shares held short 8.31M
- Feb 15, 2024: Shares held short 9.01M
- Feb 29, 2024: Shares held short 8.68M
- Mar 15, 2024: Shares held short 9.35M
- Mar 28, 2024: Shares held short 9.02M
- Apr 15, 2024: Shares held short 8.51M
- Apr 30, 2024: Shares held short 8.96M
- May 15, 2024: Shares held short 9.29M
- May 31, 2024: Shares held short 9.21M
- Jun 14, 2024: Shares held short 10.13M
- Jun 28, 2024: Shares held short 10.02M
- Jul 15, 2024: Shares held short 10.18M
- Jul 31, 2024: Shares held short 11.21M
- Aug 15, 2024: Shares held short 12.23M
- Aug 30, 2024: Shares held short 12.39M
- Sep 13, 2024: Shares held short 12.46M
- Sep 30, 2024: Shares held short 12.64M
- Oct 15, 2024: Shares held short 12.93M
- Oct 31, 2024: Shares held short 13.10M
- Nov 15, 2024: Shares held short 13.02M
- Nov 29, 2024: Shares held short 12.67M
- Dec 13, 2024: Shares held short 12.63M
- Dec 31, 2024: Shares held short 12.26M
- Jan 15, 2025: Shares held short 12.83M
- Jan 31, 2025: Shares held short 13.15M
- Feb 14, 2025: Shares held short 14.79M
- Feb 28, 2025: Shares held short 15.39M
- Mar 14, 2025: Shares held short 15.80M
- Mar 31, 2025: Shares held short 19.69M
- Apr 15, 2025: Shares held short 20.83M
- Apr 30, 2025: Shares held short 20.71M
- May 15, 2025: Shares held short 21.40M
- May 30, 2025: Shares held short 21.68M
- Jun 13, 2025: Shares held short 19.92M
- Jun 30, 2025: Shares held short 20.44M
- Jul 15, 2025: Shares held short 20.57M
- Jul 31, 2025: Shares held short 16.43M
- Aug 15, 2025: Shares held short 16.07M
- Aug 29, 2025: Shares held short 15.57M
- Sep 15, 2025: Shares held short 16.15M
- Sep 30, 2025: Shares held short 16.27M
- Oct 15, 2025: Shares held short 17.01M
- Oct 31, 2025: Shares held short 16.21M
- Nov 14, 2025: Shares held short 16.38M
- Nov 28, 2025: Shares held short 15.07M
- Dec 15, 2025: Shares held short 14.96M
- Dec 31, 2025: Shares held short 16.14M
- Jan 15, 2026: Shares held short 16.93M
- Jan 30, 2026: Shares held short 16.49M
- Feb 13, 2026: Shares held short 16.95M
- Feb 27, 2026: Shares held short 16.84M
- Mar 13, 2026: Shares held short 16.57M
- Mar 31, 2026: Shares held short 18.43M
- Apr 15, 2026: Shares held short 19.50M
- Apr 30, 2026: Shares held short 18.59M
- May 15, 2026: Shares held short 20.37M
- May 29, 2026: Shares held short 19.21M
- Jun 15, 2026: Shares held short 19.34M
- Jun 30, 2026: Shares held short 17.99M
- Jul 15, 2026: Shares held short 17.76M
- Jul 31, 2026: Shares held short 16.38M
- Aug 14, 2026: Shares held short 16.98M
- Aug 31, 2026: Shares held short 15.78M
- Sep 15, 2026: Shares held short 17.25M
- Sep 30, 2026: Shares held short 17.42M
- Oct 15, 2026: Shares held short 18.27M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading53.1% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 53.1% of the shares in the reported trades were short sales, against 52.5% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 53.1%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 52.5%
- Change
- +0.6 pts
- Short sales a dayon average, of 506.7K shares
- 269.1K
- More than atof 3,666 US-listed companies, same days
- 60%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 64.4%
- Oct 15, 2026: Short sales 51.3%
- Oct 16, 2026: Short sales 65.4%
- Oct 19, 2026: Short sales 59.7%
- Oct 20, 2026: Short sales 36.4%
- Oct 21, 2026: Short sales 86.6%
- Oct 22, 2026: Short sales 51.1%
- Oct 23, 2026: Short sales 72.1%
- Oct 26, 2026: Short sales 65%
- Oct 27, 2026: Short sales 31.8%
- Oct 28, 2026: Short sales 31.2%
- Oct 29, 2026: Short sales 44.7%
- Oct 30, 2026: Short sales 61.5%
- Nov 2, 2026: Short sales 42.2%
- Nov 3, 2026: Short sales 35.8%
- Nov 4, 2026: Short sales 54.3%
- Nov 5, 2026: Short sales 78%
- Nov 6, 2026: Short sales 28.6%
- Nov 9, 2026: Short sales 54.8%
- Nov 10, 2026: Short sales 53.4%
- Nov 11, 2026: Short sales 56.7%
- Nov 12, 2026: Short sales 61.6%
- Nov 13, 2026: Short sales 64.9%
- Nov 16, 2026: Short sales 68.3%
- Nov 17, 2026: Short sales 70.8%
- Nov 18, 2026: Short sales 61.9%
- Nov 19, 2026: Short sales 61.8%
- Nov 20, 2026: Short sales 71.4%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Roivant Sciences Ltd.Director,TenPercentOwnerDirectly113M
- Peter SalzmannChief Executive OfficerDirectly1.18M
- Julia G. ButchkoChief Development OfficerDirectly441.1K
- Eva Renee BarnettChief Financial OfficerDirectly396.8K
- William L. MaciasChief Medical OfficerDirectly357.4K
- Mark S. LevineChief Legal OfficerDirectly319.2K
- Andrew J. FromkinDirectorDirectly284.9K
- Eric VenkerChief Executive OfficerDirectly257.1K
- Tiago GiraoChief Financial OfficerDirectly234.2K
- Michael GeffnerChief Medical OfficerDirectly218.0K
- Melanie GloriaChief Operating OfficerDirectly217.1K
- Jay S StoutChief Technology OfficerDirectly198.9K
- Tuyl Christopher VanChief Legal OfficerDirectly175.2K
- Atul PandeDirectorDirectly136.7K
- Douglas J. HughesDirectorDirectly120.8K
- George Migausky VDirectorDirectly109.8K
- Robert Graham SusmanDirectorDirectly36.4K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Roivant Sciences Ltd.Director,TenPercentOwner | 113M | – | Dec 12, 2025 | Form 4 |
| Peter SalzmannChief Executive Officer | 1.18M | – | Apr 16, 2025 | Form 4 |
| Julia G. ButchkoChief Development Officer | 441.1K | – | Aug 21, 2024 | Form 4 |
| Eva Renee BarnettChief Financial Officer | 396.8K | – | Apr 16, 2025 | Form 4 |
| William L. MaciasChief Medical Officer | 357.4K | – | Feb 19, 2025 | Form 4 |
| Mark S. LevineChief Legal Officer | 319.2K | – | Nov 20, 2024 | Form 4 |
| Andrew J. FromkinDirector | 284.9K | – | May 28, 2026 | Form 4 |
| Eric VenkerChief Executive Officer | 257.1K | – | Oct 2, 2026 | Form 4 |
| Tiago GiraoChief Financial Officer | 234.2K | – | Oct 28, 2026 | Form 4 |
| Michael GeffnerChief Medical Officer | 218.0K | – | Oct 22, 2025 | Form 4 |
| Melanie GloriaChief Operating Officer | 217.1K | – | Oct 7, 2026 | Form 4 |
| Jay S StoutChief Technology Officer | 198.9K | – | Oct 21, 2026 | Form 4 |
| Tuyl Christopher VanChief Legal Officer | 175.2K | – | Oct 7, 2026 | Form 4 |
| Atul PandeDirector | 136.7K | – | Nov 11, 2026 | Form 4 |
| Douglas J. HughesDirector | 120.8K | – | Dec 1, 2025 | Form 4 |
| George Migausky VDirector | 109.8K | – | Dec 1, 2023 | Form 4 |
| Robert Graham SusmanDirector | 36.4K | – | May 1, 2026 | Form 4 |
A lower bound: it counts only the 17 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.92%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.68%
- IBBiShares Biotechnology ETFWeight in the fund0.24%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.20%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.11%
- IWMiShares Russell 2000 ETFWeight in the fund0.10%
- VBKVanguard Small-Cap Growth Index FundWeight in the fund0.09%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.07%
- VBVanguard Small-Cap Index FundWeight in the fund0.04%
- VHTVanguard Health Care Index FundWeight in the fund0.04%
19 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 187
- Q4 2025: Managers 197
- Q1 2026: Managers 216
- Q2 2026: Managers 226
Institutional investors by quarter
The fund managers holding IMVT, quarter by quarter, from Q4 2019 to Q2 2025, 23 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 226 managers held 110M shares, worth $4.3B. During the quarter 39 opened a position, 29 closed one, 71 added and 77 trimmed.
The largest holders, Q2 2026
- FMRIn the quarter-4.5%
- Deep Track CapitalIn the quarter-19%
- BlackRockIn the quarter+9.2%
- Farallon Capital ManagementIn the quarter+275%
- Baker Bros. AdvisorsIn the quarter-0.4%
- State StreetIn the quarter+1.7%
- Morgan StanleyIn the quarter+17%
- TCG Crossover ManagementIn the quarter
- Vanguard Portfolio ManagementIn the quarter+5.5%
- Vanguard Capital ManagementIn the quarter+0.5%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| FMR | 16.19M | -4.5% | $624M |
| Deep Track Capital | 9.34M | -19% | $360M |
| BlackRock | 7.18M | +9.2% | $277M |
| Farallon Capital Management | 5.81M | +275% | $224M |
| Baker Bros. Advisors | 5.44M | -0.4% | $209M |
| State Street | 4.62M | +1.7% | $178M |
| Morgan Stanley | 4.53M | +17% | $175M |
| TCG Crossover Management | 4.46M | $172M | |
| Vanguard Portfolio Management | 3.91M | +5.5% | $151M |
| Vanguard Capital Management | 3.64M | +0.5% | $140M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Immunovant's filings show?
Who buys and sells is one part of Immunovant's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have IMVT's insiders bought or sold?
From May 29, 2026 to Nov 12, 2026 Immunovant's insiders bought 0 and sold $13M of shares on the market. 3% of the sales were under set 10b5-1 plans.
Which well-known managers hold IMVT?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $37M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.